3SBio, a leading Chinese biotech with drugs for anemia and low blood platelets, priced 7.7 million shares at $16, a 23% increase from the midpoint of its range, Tuesday evening. UBS was the lead manager on the deal. The stock is expected to begin trading on Wednesday on the NASDAQ under the ticker SSRX.
